Latest Interviews
Showing 916–930 of 3,499 transcripts.
Clear all filters- Milken Institute1h 1m
Decoding Disease: Can Genetics Unlock New Interventions? | Future of Health Summit 2024
Conor Hale, Colleen Campbell, Lon Cardon, Bernard Kwabi-Addo, Benjamin Neale
Experts highlight that while genomic knowledge has expanded to 12,000 identified variants, translating these discoveries into clinical care remains hindered by insurance barriers, provider literacy gaps, and biased data representation. To overcome these bottlenecks, the field is increasingly leveraging artificial intelligence for tumor heterogeneity analysis and shifting toward deconstructing common diseases into rare, monogenic subsets for targeted therapies. With sequencing costs dropping to roughly $200, stakeholders anticipate widespread population screening programs and systematic variant analysis across human diseases becoming feasible within the next decade.
Nik Storonsky, Revolut Founder: What Revolut Needs to Do to Hit $100BN Valuation | E1233
Nik Storonsky, Harry Stebbings
Revolut CEO Nikolay Storonsky drives a strict, KPI-led leadership framework that prioritizes rapid execution and self-directed generalists, resulting in a firing rate for underperformers within the first three months. The company plans to scale its US banking operations and expand to 50 markets within three years by leveraging a UK licensing prerequisite while launching a machine learning-driven investment arm called Quantum Light. Looking ahead, Revolut aims to become the first European startup to dominate the US market by focusing on binary goal achievement and launching a private banking product for high-net-worth individuals.
- Milken Institute53 min
Health Care of the Future | Future of Health Summit 2024
Michael Milken, Alex Azar, Buddy Carter, Diana DeGette, Renee Wegrzyn
The event detailed how ARPA-H and legislative initiatives like "Cures 2.0" are addressing systemic healthcare challenges by funding high-risk biomedical innovations and ensuring pharmaceutical independence. Key figures including Rep. Diana DeGette and Rep. Chris Carter highlighted strategies to reform Medicare Advantage payment models and repatriate drug manufacturing to counter supply chain vulnerabilities. The panel concluded with a call for increased federal investment in translational science and a broader call for business leaders to enter government to sustain the pace of medical breakthroughs.
Guy Podjarny: The Future of AI Software Development - What is Real & What is BS | E1232
The speaker evaluates NVIDIA's market dominance as undervalued yet anticipates a short-term demand trough as enterprises confront the current ROI limitations of AI tools. Future technological progress is framed by massive capital requirements for general-purpose models and skepticism regarding AGI timelines in 2025 due to non-technical societal adoption barriers. Simultaneously, the discussion outlines a strategic pivot where developer roles evolve from coding to system architecture while venture capital success relies on avoiding obvious markets and timing IPOs for long-term sustainability rather than immediate exits.
- 80,000 Hours1h 24m
OpenAI's unparalleled gambit to ditch its nonprofit | UCLA legal expert Rose Chan Loui
Rose Chan Loui, Rob Wiblin, Sam Altman, Elon Musk
OpenAI intends to permanently dissolve its non-profit parent structure to form a standalone Delaware Public Benefit Corporation, a shift requiring $6.6 billion in new investor funding contingent on restructuring within two years. This transition sparks intense legal scrutiny from California and Delaware officials regarding the fair valuation of the non-profit's stake, which is estimated between $37 billion and $80 billion, to ensure the organization receives adequate cash and equity for its safety missions. While CEO Sam Altman and investors seek to remove the 100x return cap and secure broader profit rights, the non-profit board must navigate severe conflicts of interest to secure a settlement that preserves its ability to fund AI safety research.
Klaus Hommels: Why "Portfolios are Merely a Construct to Make LPs Happy"? | E1231
Klaus Hommels, Harry Stebbings
A pioneering investor articulates a strategy focused on concentrated, high-impact bets over traditional diversification, backed by lessons from early stock market triumphs and a significant loss that shaped his risk management philosophy. He critiques the European venture ecosystem for its fragmented capital markets and regulatory barriers, while simultaneously launching a defense and deep tech initiative to foster technical sovereignty against reliance on foreign military technologies. His approach prioritizes founder integrity and operational depth over financial metrics, aiming to reshape institutional investing by integrating pension capital into innovation and addressing critical gaps in government procurement.
- Milken Institute1h 11m
Global Collaboration to Eradicate Women’s Cancers | Future of Health Summit 2024
Alice Park, Usman Malami Aliyu, Danielle Carnival, Dave Fredrickson, Roberta Lipson, Gemma Peters
Global cancer leaders convened to address the projected doubling of incidence in low- and middle-income countries by implementing diverse strategies ranging from Nigeria's mobile screening vans and mobile PCR labs in China to the UK's data-driven risk assessment partnerships. These initiatives prioritize overcoming structural inequities in treatment access, financial barriers, and clinical trial participation through innovations like AI-driven imaging, drug repurposing, and targeted care navigation programs. Ultimately, the consensus emphasizes that sustainable national cancer control plans must integrate geopolitical cooperation and equity-first designs to prevent the fragmentation of global research and ensure effective prevention for the most vulnerable populations.
- Milken Institute58 min
Innovation for All: Strategies for Maximizing Impact | Future of Health Summit 2024
Matthew Herper, Jay Bradner, Debi Brooks, Lisa D. Earnhardt, Elizabeth Fowler, Marc Samuels
This event synthesized breakthroughs in Parkinson's biomarker detection, the genetic discovery of obesity-protective alleles, and strategies to expand medical device access for underserved populations. Industry leaders and regulators discussed how these scientific advances confront systemic barriers in delivery and reimbursement, particularly regarding the high costs of gene therapies and the misalignment of current billing models with preventative care. The consensus emphasized that future progress depends on shifting focus from pure biological innovation to collaborative frameworks that ensure scalable manufacturing, equitable access, and payment reforms based on patient outcomes.
- Sequoia Capital1h 3m
Getting the Most From AI With Multiple Custom Agents ft Dust’s Gabriel Hubert and Stanislas Polu
Gabriel Hubert, Stanislas Polu, Konstantine Buhler, Pat Grady
Dust positions itself as a horizontal platform for AI adoption, predicting a bimodal future where enterprise users seamlessly switch between frontier APIs and local models to navigate varying technological plateaus. By prioritizing product-market fit over proprietary model training and leveraging Retrieval-Augmented Generation to unlock data silos, the company enables diverse teams to build specialized agents that augment human work rather than replace it. This strategy targets a demographic of young power users and aims to scale from isolated pilots to organization-wide adoption, facilitating everything from cross-functional translation to global expansion despite current limitations in reasoning breakthroughs.
Jason Citron, Co-Founder/CEO @Discord: The Untold Story Behind Scaling to 200M Users | E1230
Discord founder Jason Citron recounts his strategic pivot from a fragmented "hyperscaling" phase to a centralized "Founder Mode" leadership style that prioritizes coherent product vision over decentralized autonomy. Having navigated early challenges from a failed game prototype to a $12 billion acquisition rejection, Citron now leverages AI to democratize game creation while restructuring executive hiring to emphasize cultural fit and deep contextual understanding. This approach, which replaces ceremonial meetings with asynchronous feedback and intense debate, aims to ensure Discord maintains its competitive edge and independence as it navigates the uncertain "fog of war" surrounding generative technology.
- All-In Podcast1h 10m
DOGE unveils a roadmap, Unlocking GDP Growth, WW3 escalation, Fat cell memory
Chamath, Friedberg, Jason Calacanis, David Sacks
Elon Musk and Vivek Ramaswamy's Department of Government Efficiency plans to eliminate $500 billion in unauthorized federal spending over an 18-month period by leveraging recent Supreme Court rulings to bypass traditional legislative approval processes. The initiative targets regulatory rollbacks through executive audits and temporary payment suspensions while facing anticipated legal challenges from entrenched bureaucratic interests and internal Republican resistance to deficit reduction. Concurrently, the discussion highlights global security risks regarding Western missile capabilities in the Ukraine-Russia conflict and presents scientific breakthroughs in epigenetics that explain persistent obesity mechanisms despite weight loss.
- Milken Institute1h 0m
Why Younger People Are Getting Cancer and What We Can Do About It | Future of Health Summit 2024
Dylan Scott, Karen Knudsen, Harlan Levine, Mohit Manrao, Kimryn Rathmell, AmirAli Talasaz
A comprehensive 24-million-person study spanning two decades reveals that 17 of 34 major cancer types are rising significantly among Millennials and Gen X, prompting the American Cancer Society to lower screening thresholds despite critical barriers in adoption and access. To address this "tsunami" of young survivors facing unique fertility, financial, and care challenges, the field is transitioning toward liquid biopsy innovations and multidisciplinary "living" guideline frameworks to bridge the gap between community providers and academic centers. While precision medicine and expanded immunotherapy trials offer hope for improved survival, the crisis persists due to outdated insurance models, systemic disparities, and a significant lag between emerging scientific evidence and updated clinical protocols.
Dan Fougere, CRO @Datadog: Why Discounting is Dangerous and Contract Sizes are Misleading | E1229
The event details a comprehensive enterprise sales strategy anchored by the MEDIC qualification framework, contrasting entry points for different market segments, and enforcing strict operational discipline regarding pipeline management and discount control. Speakers highlight historical case studies from Medallia and Datadog to illustrate how early "small deal" adoption can scale into major enterprise contracts while emphasizing the critical need for leadership involvement in both hiring and front-line sales activities. Ultimately, the session argues that while AI serves as a productivity multiplier, successful scaling still requires rigorous cultural foundations, specific performance metrics, and a disciplined approach to managing both junior talent and high-level stakeholder relationships.
- Milken Institute54 min
Connecting the Dots for Women's Health: Innovation, Access, & Care | Future of Health Summit 2024
Ruth Reader, Sandra Brooks, Trish Costello, Jenica Patterson, Ana Maria Ramirez, Tammy Sun
As of last week, ARPA-H has obligated $113 million in federal funding to support women's health research through Spark and Launchpad awards targeting conditions like Alzheimer's, endometriosis, and maternal mortality. This investment coincides with a 300% surge in venture capital for the sector since 2018, driving innovations in male contraception and non-pharmacological treatments despite persistent racial disparities and access barriers. While bipartisan funding provides short-term stability, experts warn that evolving legal landscapes regarding abortion and the politicization of data privacy pose significant risks to future reproductive health outcomes.
- Sequoia Capital53 min
Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution
Matthew Rabinowitz, Roelof Botha, Jonathan Sheena, Steve Chapman, Chitra Kotwaliwale, Sarah Elliot, Rolof Buerta
Co-founded by Matthew Rabinovitz and Jonathan Sheena, Natera has evolved from a specialized IVF testing provider into a global leader in genetic diagnostics, now processing 40% of U.S. pregnancies and capturing nearly half of oncologists' orders for its Signatera cancer monitoring test. The company successfully navigated significant financial volatility and strategic pivots to achieve a $1.5 billion revenue forecast, with its stock appreciating from $7 to over $100 per share following the clinical validation and market adoption of its oncology division. Today, Natera maintains a dominant market position in women's health genetics and minimal residual disease monitoring while leveraging AI to further expand its early detection capabilities across solid tumors.